Aug 12, 2013 by Max Macaluso and Dave WilliamsonMarket Checkup: MerckThe Motley Fool's health-care show with David Williamson and Max Macaluso.
Jul 21, 2013 by Max Macaluso and Dave WilliamsonWhat Are the Main Risks and Opportunities in Merck's Cholesterol Drug Franchise?A look at Merck's portfolio of lipid-lowering drugs.
Jul 21, 2013 by Max Macaluso and Dave WilliamsonCan This Struggling Drugmaker Overcome Generic Statins?AstraZeneca's leading drug Crestor facing competition from a number of cheaper generic drugs.
Jul 21, 2013 by Max Macaluso and Dave WilliamsonFDA vs. Cheerios: The Weirdest Battle in History?The FDA's warning letter to General Mills in 2009 helped the agency ensure that foods wouldn't be promoted for therapeutic purposes.
Jul 18, 2013 by Max Macaluso and Dave WilliamsonMarket Checkup: High CholesterolOur weekly healthcare show "Market Checkup" takes a look at the major pharmaceutical players in the high cholesterol space.
Jul 17, 2013 by Max MacalusoWhat's Behind St. Jude Medical's 5% Pop?Shares of St. Jude Medical climbed today after the company released Q2 results.
Jul 16, 2013 by Max MacalusoWill Novartis' Earnings Impress Wall Street?What investors need to watch in Novartis' Q2 results.
Jul 16, 2013 by Max MacalusoMerck's Progress in the Fight Against Alzheimer'sMerck is hoping for more positive results from its experimental Alzheimer's disease drug.
Jul 16, 2013 by Max MacalusoWill Abbott's Earnings Wow Wall Street?What should investors watch in tomorrow's earnings report?
Jul 14, 2013 by Max Macaluso and Dave WilliamsonWill Big Pharma Dominate the Obesity Space?Novo Nordisk and AstraZeneca might be the first "big pharma" companies to market drugs for the treatment of obesity.
Jun 30, 2013 by Max Macaluso and Dave WilliamsonMarket Checkup: ObesityIn this edition of "Market Checkup," our health-care analysts discuss emerging treatments for obesity.
Jun 26, 2013 by Max MacalusoIs This Billion-Dollar Diabetes Drug Class Doomed?A look at Merck's most important drugs.
Jun 26, 2013 by Max MacalusoAsk a Fool: What Will Belviq's Launch Do for Arena?Could Arena Pharmaceuticals' new obesity drug Belviq be facing headwinds right from the start?
Jun 26, 2013 by Max MacalusoAsk a Fool: What's Up With MAKO Surgical?What does a Fool think of MAKO Surgical stock today?
Jun 26, 2013 by Max Macaluso and Dave WilliamsonThe Market Checkup: Type 2 DiabetesWhat should investors know about the leading drugmakers in the type 2 diabetes space?
Jun 21, 2013 by Max MacalusoDown 30%: What Caused Idenix's Crash?Why did shares of Idenix crash today?
Jun 19, 2013 by Max MacalusoSarepta Pops on More Positive DataWhat was behind this development-stage biotech's pop?
Jun 19, 2013 by Max MacalusoWill Amarin's Fish Oil Drug Slip Past the FDA a Second Time?The advisory committee meeting date for the ANCHOR indication is now set.
Jun 17, 2013 by Max MacalusoDoes Restless Legs Syndrome Really Shorten Life Span?A new study suggests a link between this neurological disorder and mortality rates in men.
